June 2026 in “Cancer Research Communications” In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.
451 citations
,
March 2005 in “Endocrine Reviews” This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” This case report describes a woman with hypertension, alopecia, and other symptoms, revealing that her condition was due to ovarian hyperthecosis, highlighting the overlap of adrenal and ovarian disorders.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
34 citations
,
November 2017 in “Gynecological Endocrinology” This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.
